The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
Gao, S., Wu, Ding, Gao, Wang, Fan, Wang, Zhang, Wang, Ye, et al. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s23747 · Cited by 111
RetractedAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Early studies on liposomes focused on passive delivery that target cancerous tissues through the EPR effect, such as long-circulating liposomes [46].”
BackgroundTherapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J., & Kissel, T. (2003) · Biomaterials · doi:10.1016/s0142-9612(02)00445-3 · Cited by 2,329
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
An overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693
Cationic lipids, lipoplexes and intracellular delivery of genes
Wasungu, L., & Hoekstra, D. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.024 · Cited by 595
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery
Guo, J., Gao, X., Su, L., Xia, H., Gu, G., Pang, Z., Jiang, X., Yao, L., Chen, J., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.004 · Cited by 566
Molecular dissection of nucleolin's role in growth and cell proliferation: new insights
Srivastava, M., & Pollard, H. B. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1911 · Cited by 494
Discovery and development of anticancer aptamers
Ireson, C. R., & Kelland, L. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0172 · Cited by 481
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States
Jemal, A., Devesa, S. S., Hartge, P., & Tucker, M. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.678 · Cited by 449
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Regulatory pathways governing HIV-1 replication
Cullen, B. R., & Greene, W. C. (1989) · Cell · doi:10.1016/0092-8674(89)90420-0 · Cited by 396
Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., & Zalipsky, S. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00085-h · Cited by 288
Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles
Gao, H., Qian, J., Cao, S., Yang, Z., Pang, Z., Pan, S., Fan, L., Xi, Z., Jiang, X., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.058 · Cited by 280
Self-citationNear-Infrared Fluorescent RGD Peptides for Optical Imaging of Integrin αvβ3Expression in Living Mice
Cheng, Z., Wu, Y., Xiong, Z., Gambhir, S. S., & Chen, X. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0501698 · Cited by 234
Self-citationVirosomes: evolution of the liposome as a targeted drug delivery system
Kaneda, Y. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00069-7 · Cited by 207
Qi, J., Dai, Zhou, Lu, Y., Wu, W., & Liu (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44487 · Cited by 176
Kim, J. K., Choi, K.-J., Lee, M., Jo, M.-H., & Kim, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.023 · Cited by 174
Kim, E., Jung, Y., Choi, H., Yang, J., Suh, J., Huh, Y., Kim, K., & Haam, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.030 · Cited by 157
Đapić, V., Bates, P. J., Trent, J. O., Rodger, A., Thomas, S. D., & Miller, D. M. (2002) · Biochemistry · doi:10.1021/bi0119520 · Cited by 140
Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (−) prostate cancers
Min, K., Jo, H., Song, K.-M., Cho, M., Chun, Y., Jon, S., Kim, W. J., & Ban, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.035 · Cited by 137
Tong, R., Yala, L., Fan, T. M., & Cheng, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.009 · Cited by 135
Gao, J., Liu, W., Xia, Y., Li, W., Sun, J. F., Chen, H., Li, B., Zhang, D., Qian, W., Meng, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.034 · Cited by 127
Self-citationNucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs Delivery
Wu, J., Song, C., Jiang, C., Shen, X., Qiao, Q., & Hu, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300686g · Cited by 125
Cyclic Arg-Gly-Asp Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats
Du, S.-L., Pan, H., Lu, W., Wang, J., Wu, J., & Wang, J.-Y. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122481 · Cited by 120
GMP Production of Liposomes—A New Industrial Approach
Wagner, A., Platzgummer, M., Kreismayr, G., Quendler, H., Stiegler, G., Ferko, B., Vecera, G., Vorauer‐Uhl, K., & Katinger, H. (2006) · Journal of Liposome Research · doi:10.1080/08982100600851086 · Cited by 107
Basarkar, A., Devineni, D., Palaniappan, R., & SINGH, J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.023 · Cited by 98
Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome
Igarashi, S., Hattori, Y., & Maitani, Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.03.003 · Cited by 78
Human stem cell-based three-dimensional microtissues for advanced cardiac cell therapies
Emmert, M. Y., Wolint, P., Wickboldt, N., Gemayel, G., Weber, B., Brokopp, C. E., Boni, A., Falk, V., Bosman, A., Jaconi, M. E., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.034 · Cited by 75
Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Collins, S., Guinn, B., Harrison, P. T., Scallan, M. F., O’Sullivan, G. C., & Tangney, M. (2008) · Current Gene Therapy · doi:10.2174/156652308784049345 · Cited by 72
Kim, C. J., Dessureault, S., Gabrilovich, D., Reintgen, D. S., & Slingluff, C. L. (2002) · Cancer Control · doi:10.1177/107327480200900104 · Cited by 69
Antibody Engineering Promotes Nanomedicine for Cancer Treatment
Gao, J., Feng, S., & Guo, Y. (2010) · Nanomedicine · doi:10.2217/nnm.10.94 · Cited by 59
Self-citationBRAF mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer
Zerilli, M., Zito, G., Martorana, A., Pitrone, M., Cabibi, D., Cappello, F., Giordano, C. S. D. S., & Rodolico, V. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.86 · Cited by 58
Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis
Li, F., Sun, J., Wang, J., Du, S., Lu, W., Liu, M., Xie, C. L., & Shi, J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.021 · Cited by 55
Cited by
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
Self-citationDrug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202100639 · Cited by 418
Metadata
- Authors
- Li, L., Hou, J., Liu, X., Guo, Y., Wu, Y., Zhang, L., & Yang, Z.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 35
- Issue
- 12
- Pages
- 3840-3850
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W1985247850
- Cited by
- 289
- References
- 46
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.